Wednesday, 08 April 2020

Dr Reddy's launches generic fracture drug

07 March 2013 | News | By BioSpectrum Bureau

Good news for cancer patients who suffer fractures - Dr Reddy's Laboratories launches generic version of Novartis Zometa Injection

Good news for cancer patients who suffer fractures - Dr Reddy's Laboratories launches generic version of Novartis Zometa Injection

Hyderabad: Dr Reddy's Laboratories (DRL) launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Novartis' Zometa (zoledronic acid) 4 mg/5 mL Injection in the US.

The product was launched following the approval by the US Food & Drug Administration (US FDA) of Dr Reddy's Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/5 mL).

Dr Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account